"It's really amazing to see it when it works," she said
Sejaro is also used to treat adults with obesity (body mass index (BMI): NLT 30 kg/m) or adults with overweight (BMI: NLT 27 kg/m), having such concomitant conditions as pre-diabetes or type 2 diabetes mellitus, high blood pressure, abnormal blood fat level, trouble breathing during sleep (called as obstructive sleep apnoea) or cardiovascular diseases
The SURPASS-1 trial demonstrated significant improvements in glycemic control and substantial reductions in body weight with all three doses of tirzepatide (5 mg, 10 mg, or 15 mg) compared to placebo over a 40-week period
Whats the Right Cold Chain Packaging for GLP-1 Medications
By distribution channel, hospital pharmacies led with 64.72% revenue share in 2025, whereas online and tele-pharmacies record the highest projected CAGR at 6.88% to 2031
Generally, candidates for GLP-1 medications like Saxenda have a Body Mass Index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity, such as type 2 diabetes, high blood pressure, or high cholesterol